BioCentury | Jun 30, 2020
Product Development

Low-stakes 2018 deal with Regeneron leads to bump for Kiniksa on pericarditis readout

...enrolled actively symptomatic recurrent pericarditis patients who were failing standard-of-care therapy including non-steroidal anti-inflammatory steroids, colchicine...
BioCentury | Nov 18, 2019

Microtubule inhibitors including colchicine for myotonic dystrophy

...DISEASE CATEGORY: Musculoskeletal INDICATION: Myotonic dystrophy type 1 (DM1) Colchicine and other microtubule inhibitors could treat...
...HeLa cells identified three microtubule inhibitors, colchicine, thiocolchicine and suprafenacine, among the top five hits. Colchicine...
...protein biomarker. Next steps include evaluating whether colchicine can reverse DM1 phenotypes in animal models. Colchicine...
BioCentury | Dec 15, 2018
Politics & Policy

Firdapse re-catalyzes pricing debate

...public finds unconscionable. This happened in 2010, when URL Pharma Inc. gained approval for Colcrys colchicine...
...of acute gout and seven years of Orphan Drug exclusivity for treating familial Mediterranean fever. Colchicine...
...has been used to treat gout for over 3,000 years. URL set the price of Colcrys...
BioCentury | Jan 12, 2017
Clinical News

Kineret: Ph II anaGO started

...triamcinolone acetonide (TCA) vs. TCA alone in about 159 patients who cannot take NSAIDs and colchicine...
BioCentury | Sep 12, 2016
Politics, Policy & Law

Executive power

...publicized as the Makena compounding decision. In 2009, Sharfstein held up FDA approval of Colcrys colchicine...
BioCentury | Jan 18, 2016
Politics, Policy & Law

Compounding prices

...both times. In 2009, FDA reviewed an application from URL Pharma Inc. for Colcrys colchicine. Colchicine...
...single-ingredient colchicine on the market. FDA officials knew Colcrys' approval was a double-edged sword. Unapproved colchicine...
...potency and purity had killed at least 117 Americans, according to FDA, so approval of Colcrys...
BioCentury | Oct 5, 2015
Clinical News

Bucillamine: Interim Phase IIa data

...in 25% and 67% of patients, respectively, vs. 42% of patients receiving 1.8 mg oral colchicine...
BioCentury | Mar 2, 2015
Clinical News

Arhalofenate: Phase IIb data

...of once-daily arhalofenate led to a flare rate of 1.04, and allopurinol plus 0.6 mg colchicine...
...baseline to week 12 by 29% when given alone and by 25% when given with colchicine...
BioCentury | Feb 2, 2015
Clinical News

Arhalofenate: Preliminary Phase II data

...In the final 2 weeks, patients received 80 mg febuxostat as monotherapy. Patients also received colchicine...
BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Tubulin

...that could help treat cancer. Chemical synthesis and testing in a tubulin polymerization assay of colchicine...
Items per page:
1 - 10 of 65